A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a randomized, double-masked, placebo-controlled Phase II clinical trial. The primary objective is to explore the efficacy of G01 Eye Drops in the treatment of optic nerve injury associated with open-angle glaucoma, providing supportive evidence for the design of subsequent clinical trials. The secondary objectives are to evaluate the safety, pharmacokinetic profiles, and immunogenicity of G01 Eye Drops in the target patient population.
Epistemonikos ID: 1c9532221bfba3c7ee1ca577ffa0ea73078d0ada
First added on: Aug 20, 2026